XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment … Read more
XORTX Therapeutics Inc (XRTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.343x
Based on the latest financial reports, XORTX Therapeutics Inc (XRTX) has a cash flow conversion efficiency ratio of -0.343x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-978.26K) by net assets ($2.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
XORTX Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how XORTX Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
XORTX Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XORTX Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
West Cobar Metals Ltd
AU:WC1
|
-0.166x |
|
Lewis Group Limited
JSE:LEW
|
-0.019x |
|
Star Gold Corp
OTCQB:SRGZ
|
0.179x |
|
Cibox Inter@ctive S.A.
PA:ALCBX
|
-0.400x |
|
NORFOLK SOUTHERN (NFS.SG)
STU:NFS
|
0.089x |
|
Vessel Co. Ltd
KQ:177350
|
-0.209x |
|
Origin Global Empire Public Company Limited
BK:EMPIRE
|
0.042x |
|
Silver Range Resources Ltd
PINK:SLRRF
|
-0.012x |
Annual Cash Flow Conversion Efficiency for XORTX Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of XORTX Therapeutics Inc from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.85 Million | $-3.87 Million | -1.354x | -22.81% |
| 2024-12-31 | $3.34 Million | $-3.68 Million | -1.103x | +22.26% |
| 2023-12-31 | $4.64 Million | $-6.58 Million | -1.418x | -12.17% |
| 2022-12-31 | $6.97 Million | $-8.82 Million | -1.264x | -343.91% |
| 2021-12-31 | $16.70 Million | $-4.75 Million | -0.285x | +61.48% |
| 2020-12-31 | $985.17K | $-728.40K | -0.739x | -162.72% |
| 2019-12-31 | $-211.72K | $-249.58K | 1.179x | +124.37% |
| 2018-12-31 | $321.54K | $-1.56 Million | -4.837x | -3373.16% |
| 2017-12-31 | $-654.63K | $91.17K | -0.139x | -140.97% |
| 2016-12-31 | $-317.06K | $-107.78K | 0.340x | +138.17% |
| 2014-12-31 | $119.93K | $-106.80K | -0.891x | -- |